Kratom as a Therapeutic Option for Opioid Use Disorder: A Comprehensive Review

Kratom (Mitragyna speciosa) has gained significant attention for its potential role in managing opioid use disorder (OUD). This review examines kratom’s pharmacology, safety profile, addiction potential, and ethical considerations in research, while exploring its future as a therapeutic option. Kratom’s primary alkaloids, mitragynine and 7-hydroxymitragynine, act as partial mu-opioid receptor agonists, producing analgesic and sedative effects at higher doses and stimulant-like effects at lower doses. Preclinical and observational studies suggest kratom may alleviate opioid withdrawal symptoms and cravings, but concerns remain regarding its dependency potential and adverse effects, including gastrointestinal distress, hepatotoxicity, and withdrawal symptoms upon cessation. While kratom carries a lower risk of fatal overdose compared to traditional opioids, its safety and efficacy in OUD treatment remain inadequately studied due to a lack of standardized clinical trials and regulatory oversight. Ethical concerns in kratom research include ensuring informed consent, minimizing risks to vulnerable populations, and addressing conflicts of interest in industry-funded studies. Future research must prioritize randomized controlled trials, product standardization, and long-term safety assessments to determine kratom’s viability as an alternative or adjunct to FDA-approved OUD treatments. Effective regulation informed by scientific findings is essential to maximize therapeutic benefits while minimizing harm.